Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Peritoneal Dialysis Patients With Residual Kidney Function
NCT05715814Phase 3Recruiting
- Sponsor
- University Health Network
- Start
- Sep 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of empagliflozin in Kidney disease, sponsored by University Health Network. Primary endpoint: Change in measured Glomerular Filtration Rate at 2 weeks. Started Sep 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Kidney disease
Beyond the preview
Go deeper on NCT05715814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715814.